02659nas a2200277 4500000000100000008004100001260003400042653002900076653001300105653002000118653004300138653002000181100001100201700001300212700001600225700001500241700001500256700001400271700001600285245016100301856008700462300001400549490000700563520178600570022002502356 2024 d bOxford University Press (OUP)10aMass drug administration10aModeling10aSchistosomiasis10aElimination as a public health problem10aNever treatment1 aKura K1 aMutono N1 aBasáñez M1 aCollyer BS1 aCoffeng LE1 aThumbi SM1 aAnderson RM00aHow Does Treatment Coverage and Proportion Never Treated Influence the Success of Schistosoma mansoni Elimination as a Public Health Problem by 2030? uhttps://academic.oup.com/cid/article-pdf/78/Supplement_2/S126/57334394/ciae074.pdf aS126-S1300 v783 a
Background: The 2030 target for schistosomiasis is elimination as a public health problem (EPHP), achieved when the prevalence of heavy-intensity infection among school-aged children (SAC) reduces to <1%. To achieve this, the new World Health Organization guidelines recommend a broader target of population to include pre-SAC and adults. However, the probability of achieving EPHP should be expected to depend on patterns in repeated uptake of mass drug administration by individuals.
Methods: We employed 2 individual-based stochastic models to evaluate the impact of school-based and community-wide treatment and calculated the number of rounds required to achieve EPHP for Schistosoma mansoni by considering various levels of the population never treated (NT). We also considered 2 age-intensity profiles, corresponding to a low and high burden of infection in adults. .
Results: The number of rounds needed to achieve this target depends on the baseline prevalence and the coverage used. For low- and moderate-transmission areas, EPHP can be achieved within 7 years if NT ≤10% and NT <5%, respectively. In high-transmission areas, community-wide treatment with NT <1% is required to achieve EPHP.
Conclusions: The higher the intensity of transmission, and the lower the treatment coverage, the lower the acceptable value of NT becomes. Using more efficacious treatment regimens would permit NT values to be marginally higher. A balance between target treatment coverage and NT values may be an adequate treatment strategy depending on the epidemiological setting, but striving to increase coverage and/or minimize NT can shorten program duration.
a1058-4838, 1537-6591